These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 34736865)

  • 1. Analysis of naloxone access and primary medication nonadherence in a community pharmacy setting.
    Connolly E; McCall KL; Couture S; Felton M; Piper BJ; Bratberg JP; Tu C
    J Am Pharm Assoc (2003); 2022; 62(1):49-54. PubMed ID: 34736865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
    Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
    Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
    Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
    [No Abstract]   [Full Text] [Related]  

  • 8. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
    Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
    J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
    Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
    Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
    Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
    J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between a State Law Allowing Pharmacists to Dispense Naloxone Without a Prescription and Naloxone Dispensing Rates.
    Gangal NS; Hincapie AL; Jandarov R; Frede SM; Boone JM; MacKinnon NJ; Koechlin K; DeFiore-Hyrmer J; Holthusen A; Heaton PC
    JAMA Netw Open; 2020 Jan; 3(1):e1920310. PubMed ID: 32003819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Cost Sharing and Naloxone Prescription Dispensing.
    Chua KP; Conti RM; Lagisetty P; Bohnert AS; He S; Nguyen TD
    JAMA; 2024 Jul; 332(2):124-132. PubMed ID: 38869887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
    Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
    J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.